Genentech Reports Positive Progression-Free Survival Results For Avastin In Brain Cancer Trial

Interim results of a Phase II study showed that 51 percent of patients receiving Avastin plus chemotherapy experienced six months of PFS, and 36 percent of patients taking Avastin alone had six-month PFS.